Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) shot up 3.8% during trading on Monday . The stock traded as high as $12.74 and last traded at $12.44, with a volume of 53,592 shares trading hands. The stock had previously closed at $11.99.

Several research firms recently commented on AIMT. Piper Jaffray Cos. reissued an “overweight” rating and set a $38.00 target price on shares of Aimmune Therapeutics in a research note on Tuesday, April 12th. Wedbush reissued an “outperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Finally, Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, May 20th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $33.40.

The stock’s market cap is $527.24 million. The stock’s 50 day moving average price is $11.59 and its 200-day moving average price is $13.95.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.03. Equities research analysts forecast that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current fiscal year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the firm’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. Aisling Capital LLC raised its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 6.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,990,000 shares of the company’s stock after buying an additional 170,000 shares during the period. Aimmune Therapeutics accounts for 9.5% of Aisling Capital LLC’s portfolio, making the stock its 4th largest position. Aisling Capital LLC owned 7.08% of Aimmune Therapeutics worth $55,166,000 as of its most recent SEC filing.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.